Superior Results Of The Comparative Study Of The Company's Recombinant Two-Component COVID-19 Vaccine ReCOV As Compared To International Mainstream mRNA Vaccine |
| December 14, 2022 | December 2022 Bond Updates |
|
TAIZHOU, China, Dec. 14, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that positive results were achieved for its sequential booster vaccination Phase II study of the recombinant twocomponent... |
| View more at: https://www.prnewswire.com:443/news-releases/superior-results-of-the-comparative-study-of-the-companys-recombinant-two-component-covid-19-vaccine-recov-as-compared-to-international-mainstream-mrna-vaccine-301702595.html |
| Related News |